- Medically Reviewed by: Mr Mfazo Hove, Consultant Ophthalmic Surgeon
- Author: Mr Mfazo Hove
- Published: February 8, 2025
- Last Updated: August 18, 2026
TL;DR: The Best ICL Surgery in the UK Is a Lifecycle, Not an Operation
The underlying Implantable Collamer Lens (ICL) technology is standardised; what varies between providers is the assessment, sizing, surgical judgement and long-term pathway around it. So the best ICL surgery in the UK cannot be defined by the relatively brief episode in theatre. It is defined by the specification of everything around it, from the honesty of your first assessment to the plan for the decades after your last routine review. This page is that specification, stage by stage, written so that a patient who has never heard of Blue Fin Vision® can finish it knowing what “best” should mean and how to test any UK provider against it, including us. The surgeon-level case is made separately in Who Is the Best ICL Surgeon in the UK?
Here is the fact that should shape your entire choice of provider: an ICL is not an event. It is a decades-long relationship. The lens sits inside your eye, in front of your natural lens, and it needs to be respected for as long as it is there: the vault, the space between ICL and natural lens, should be checked, and your corneal endothelial cell count monitored over the years. ¹ And if, in later life, your natural lens develops a cataract, the ICL is removed as part of the transition to cataract surgery and an intraocular lens. Providers differ substantially in what happens after routine postoperative follow-up: ask specifically what monitoring is offered after year one, how long it continues and whether it is included in the original fee. The Blue Fin Vision® pathway is designed for the entire life of the lens.
Am I Suitable for an ICL in the First Place?
An Implantable Collamer Lens is a soft phakic lens placed in the posterior chamber of the eye, behind the iris and in front of your natural crystalline lens, which stays in place and keeps working. Modern designs incorporate a central port that allows the eye’s own fluid to circulate through the lens, and the published record for effectiveness and safety, from the original FDA trial through to modern central-port reviews, is strong. ¹ ² ³ Typical candidates are adults with stable prescriptions, often with higher myopia or corneal parameters that constrain safe laser ablation. But suitability is established by measurement, not by category: your refraction must be stable; your anterior chamber must physically accommodate the lens with an appropriate vault; your endothelium must be healthy, recorded as a baseline count; your natural lens must be clear; your retina healthy; your ocular surface honestly assessed, because an ICL should not be presented as a treatment for dry eye itself; and your expectations matched to what the optics can deliver. A credible ICL assessment must be capable of ending with a recommendation not to proceed.
Why ICL Rather Than Laser?
Sometimes it should not be. Laser remains excellent for suitable corneas, and the decision logic is specific: corneal thickness and topography, because laser removes tissue and the ICL does not; prescription magnitude, because very high corrections favour the implant’s optical quality; ocular surface status; screening for corneal risk, which remains fundamental whichever road is taken; ⁴ age and lens status, because an ageing lens often makes lens replacement the honest recommendation instead; ⁵ and reversibility, because the ICL is designed to be removable while laser is not. The best ICL surgery in the UK therefore sits inside a practice that also offers the alternatives, so the recommendation can follow the eye rather than being constrained by a single treatment modality.
What Actually Happens During ICL Surgery?
The operation itself is a relatively brief episode, performed as a day case under anaesthetic drops. The folded ICL is introduced through a small opening at the edge of the cornea, unfolds inside the eye, and is positioned behind the iris in front of your natural lens. There are no sutures in routine cases, nothing to handle afterwards, and most patients notice a substantial visual improvement quickly. The brevity is precisely why this page keeps insisting that the operation is the smallest part of the specification: the judgement was exercised before theatre, and the responsibility continues long after it.
Toric ICL: Correcting Astigmatism Within the Same Implant
Many ICL patients also have astigmatism, and the toric ICL corrects it within the same lens: the United States FDA trial of the toric ICL demonstrated effective correction of moderate to high myopic astigmatism across 210 eyes. ⁶ Toric correction only works on the intended axis, so precise planning and placement matter, and a toric ICL that rotates away from its axis loses effect and may need repositioning. A provider offering toric ICLs should be able to describe both the planning and the repositioning pathway before you ask.
The First Month: Vault, Pressure, Recovery
Early reviews confirm three things: that the measured vault matches the predicted one, that intraocular pressure is normal, and that vision is recovering as expected. This is also where the rare early problems declare themselves, and where an established pathway matters more than reassurance.
What Vault Actually Means, and Why It Follows You
Vault is the clearance between the back of the ICL and the front of your natural lens, and sizing the ICL to achieve an appropriate vault is among the most important technical considerations in the entire procedure. A vault that is too low brings the ICL close to the natural lens; too high can crowd the drainage structures at the front of the eye. The clinical significance of an unusual vault depends on its degree and what is happening elsewhere in the eye, which is why vault is measured rather than assumed, and why it remains relevant beyond the first postoperative visit: long-term follow-up shows vault can change gradually over the years. ⁷ The best ICL surgery treats vault as a number that is predicted, then measured, then followed.
Why the Endothelium Matters, and How It Should Be Monitored
The corneal endothelium, the single layer of cells that keeps your cornea clear, has very limited regenerative capacity in vivo, which is why endothelial cell density matters before implantation and during long-term follow-up. Modern central-port designs have a reassuring published safety profile, and ten-year follow-up of low- and normal-vault eyes reported endothelial cell density loss of approximately 3.8% to 4.5% at ten years, ⁷ but a published average is not your eye. The specification is simple: a baseline count recorded before surgery, and monitoring at defined intervals afterwards, under a structure like the Lifetime Monitoring Protocol™, so that year ten is interpreted against year zero rather than guesswork.
If the Prescription Changes
A symptomatic residual or later refractive error may, where clinically appropriate, be managed with corneal refractive enhancement or, in selected circumstances depending on the cause, ICL repositioning, exchange or another refractive strategy. At Blue Fin Vision®, enhancement for eligible self-pay ICL patients is fully covered within 24 months under the written Enhancement Policy, and repositioning and exchange sit within our own surgical pathway. Different problems have different solutions; the specification is that the pathways exist and are written down.
Exchange and Removal: Uncommon, but Specified
The ICL is designed to be removable, one of its genuine virtues, and the contemporary evidence is reassuring on frequency: in a recent high-volume United States series of 961 EVO ICL eyes, the size-related exchange or explant rate was 1.1%, with toric rotation accounting for six exchanges and five eyes exchanged because of initial vault concerns. ⁸ Exchange is uncommon. A serious provider should nevertheless have a pathway for it, within its own surgical system rather than by onward referral.
If Cataract Develops
ICL surgery preserves your natural lens; it does not stop it ageing. Many patients implanted young may eventually require cataract surgery later in life, at which point the ICL is removed as part of the transition to cataract surgery and an intraocular lens. The specification test is whether that plan exists in writing today, within the system that implanted the lens. At Blue Fin Vision® it does, inside the Advantage, and the surgeon who leads that system has personally undergone cataract surgery himself.
If You Move City or Country
Ask any provider what happens to your data. Your baseline endothelial count, sizing rationale, predicted and measured vault and every subsequent measurement should be recorded so they can travel with you, because whoever monitors your eye in twenty years, here or abroad, will need year zero to interpret year twenty.
Best ICL Surgery UK: What Should the Fee Include?
Provider policies vary: enhancement may be included for a defined period, subject to eligibility, charged separately or handled under provider-specific terms. Ask to see the written policy before surgery, and ask the same question of monitoring visits, exchange if ever required, and the eventual cataract pathway. Ours are published before you pay:
Who Monitors My Vault and Endothelial Cells Over the Years?
- Approaches you may encounter elsewhere: Follow-up may end at the final post-operative review; ask what is offered beyond it.
- Blue Fin Vision®: The Lifetime Monitoring Protocol™ provides structured lifelong vault and endothelial monitoring at defined intervals within one system.
What If My Result Needs Fine-Tuning?
- Approaches you may encounter elsewhere: Provider policies vary: enhancement may be included for a defined period, charged separately or handled under provider-specific terms; ask to see the written policy before surgery.
- Blue Fin Vision®: Enhancement for eligible self-pay ICL patients is fully covered within 24 months, with no cost-sharing, in writing before surgery.
If I Develop a Cataract in Later Life, What Happens?
- Approaches you may encounter elsewhere: This is often outside the original provider’s scope entirely; ask who removes the ICL and what it costs.
- Blue Fin Vision®: A written position on the ICL-to-cataract transition, planned within the same clinical system that implanted the lens.
Who Removes or Exchanges the ICL If Ever Needed?
- Approaches you may encounter elsewhere: This may involve onward referral; ask.
- Blue Fin Vision®: Removal and exchange capability within Blue Fin Vision®’s own surgical pathway.
How Blue Fin Vision® Meets This Specification
- Consultant-led assessment spanning ICL, laser and lens replacement, so the recommendation can follow the eye rather than being constrained by a single treatment modality.
- Anterior segment measurement for sizing, a predicted vault stated before surgery and a measured vault checked after it, and a recorded baseline endothelial cell count for every eye.
- Surgery performed by the consultant who assessed you, with more than 57,000 procedures behind the practice, including over 25,000 in the last four years.
- Structured lifelong vault and endothelial monitoring at defined intervals under the Lifetime Monitoring Protocol™.
- Written enhancement coverage for eligible self-pay ICL patients within 24 months under the Enhancement Policy, repositioning and exchange within our own surgical pathway, and a written ICL-to-cataract transition inside the Blue Fin Vision® Advantage.
- Six consecutive years of published, audited cataract surgery outcomes, the measurement culture the ICL pathway inherits.
The system behind all of this is published: the Blue Fin Vision® Advantage, the Enhancement Policy, the ICL Surgery Checklist to test any provider against, including us, and transparent pricing on the ICL costs page.
Where Blue Fin Vision® Provides ICL Care
One governance model across the network: the Harley Street Eye Centre, Weymouth Street Hospital and Chase Lodge Hospital in London, One Hatfield Hospital in Hertfordshire and Phoenix Hospital Chelmsford in Essex, with assessments and long-term monitoring provided across the network and surgery at our surgical centres, confirmed for your case at consultation. Patients travel from across the UK; for the London-specific decision, see Best Place to Get ICL Surgery in London?
So, Where Is the Best ICL Surgery in the UK?
Wherever the whole lifecycle is specified in writing, from your baseline measurements to the year-twenty plan. You arrived here searching for “best ICL surgery UK”; you now know what “best” should mean. Hold every provider’s pathway, including ours, against the same stages, and let the gaps answer for themselves.
Book a consultation to find out whether your eyes are suitable and discuss your options with a consultant-led UK clinic providing ICL care with documented outcomes across London, Hertfordshire and Essex.
References
- Packer M. The Implantable Collamer Lens with a central port design: review of the literature. Clin Ophthalmol. 2018;12:2427-2438. PMID: 30568421.
- Packer M. Meta-analysis and review: effectiveness, safety, and central port design of the intraocular collamer lens. Clin Ophthalmol. 2016;10:1059-1077. PMID: 27354760.
- Sanders DR, Doney K, Poco M; ICL in Treatment of Myopia Study Group. United States Food and Drug Administration clinical trial of the Implantable Collamer Lens (ICL) for moderate to high myopia: three-year follow-up. Ophthalmology. 2004;111(9):1683-1692. PMID: 15350323.
- Randleman JB, Woodward M, Lynn MJ, Stulting RD. Risk assessment for ectasia after corneal refractive surgery. Ophthalmology. 2008;115(1):37-50. PMID: 17624434.
- Maldonado MJ, de Salazar Campos A, Castro Machado A. Indications and risk factors in refractive lens exchange: outcomes and special cases (extreme hyperopes and myopes). Arch Soc Esp Oftalmol (Engl Ed). 2026. Online ahead of print. doi:10.1016/j.oftale.2026.502616. PMID: 42476410.
- Sanders DR, Schneider D, Martin R, Brown D, Dulaney D, Vukich J, Slade S, Schallhorn S. Toric Implantable Collamer Lens for moderate to high myopic astigmatism. Ophthalmology. 2007;114(1):54-61. PMID: 17198849.
- Alfonso-Bartolozzi B, Fernández-Vega-Cueto L, Lisa C, Palacios A, Madrid-Costa D, Alfonso JF. Ten-year follow-up of posterior chamber phakic intraocular lens with central port design in patients with low and normal vault. J Cataract Refract Surg. 2024;50(5):441-447. doi:10.1097/j.jcrs.0000000000001379. PMID: 38085219.
- Hirabayashi M, Virdi G, Nasser T, Libfraind L, Zapata EA, Abramson AJ, Parkhurst G. ICL exchanges or explants due to sizing in a United States high volume center. Clin Ophthalmol. 2025;19:2609-2614. doi:10.2147/OPTH.S528280. PMID: 40800717.
ABOUT THE AUTHOR
Mr Mfazo Hove
Consultant Ophthalmic Surgeon
MBChB MD FRCOphth CertLRS
Mr Mfazo Hove is a Consultant Ophthalmic Surgeon with experience spanning more than 57,000 procedures. He completed 6.5 years of specialist training at Moorfields Eye Hospital and served for five years as a consultant at the Western Eye Hospital, Imperial College Healthcare NHS Trust. He is the founder of Blue Fin Vision®, a consultant-led private ophthalmology practice operating across London, Essex, and Hertfordshire. His clinical expertise encompasses advanced cataract surgery, refractive lens replacement, laser vision correction, and implantable Collamer lenses (ICL).
A ZEISS Key Opinion Leader, Mr Hove is a respected international speaker with five invited engagements across seven cities in 2026:
- ZEISS China tour (Changsha, Shanghai, and Hangzhou, April – ZEISS APAC User Meeting)
- RCOphth Annual Congress – May – Manchester
- ZEISS EMEA User Meeting (Istanbul)
- ZEISS Lausanne User Meeting (Lausanne)
- European Society of Cataract and Refractive Surgeons Annual Congress (ESCRS, London)
